Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial
By Julie Steenhuysen CHICAGO (Reuters) – The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk factor for heart disease in a midstage trial, according to data presented at a major medical meeting on Sunday. The drug, lepodisiran, reduced levels of lipoprotein(a), orLp(a), by an average …
Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial Read More »









